Sung H et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71(3):209–249

Article  PubMed  Google Scholar 

Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74(1):12–49

Article  PubMed  Google Scholar 

Ferraldeschi R et al (2015) Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene 34(14):1745–1757

Article  CAS  PubMed  Google Scholar 

Buttigliero C et al (2015) Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. Cancer Treat Rev 41(10):884–892

Article  CAS  PubMed  Google Scholar 

Schmidt M et al (2017) Regulation of G2/M Transition by Inhibition of WEE1 and PKMYT1 Kinases. Molecules, 22(12)

Matheson CJ, Backos DS, Reigan P (2016) Targeting WEE1 Kinase in Cancer. Trends Pharmacol Sci 37(10):872–881

Article  CAS  PubMed  Google Scholar 

Kim HY et al (2016) Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer. Oncotarget 7(31):49902–49916

Article  PubMed  PubMed Central  Google Scholar 

Seligmann JF et al (2021) Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring. J Clin Oncol 39(33):3705–3715

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bauer TM et al (2023) A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors. Target Oncol 18(4):517–530

Article  PubMed  PubMed Central  Google Scholar 

Qiao X et al (2021) The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML. Blood Cancer J 11(6):111

Article  PubMed  PubMed Central  Google Scholar 

Fu XH et al (2019) CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression. Acta Pharmacol Sin 40(5):677–688

Article  CAS  PubMed  Google Scholar 

Li X et al (2021) The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia. Haematologica 106(5):1262–1277

CAS  PubMed  Google Scholar 

Hu C et al (2020) CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action. J Cell Mol Med 24(13):7239–7253

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pal S et al (2018) Dual HDAC and PI3K Inhibition Abrogates NFkappaB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas. Cancer Res 78(14):4007–4021

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hirai H et al (2009) Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther 8(11):2992–3000

Article  CAS  PubMed  Google Scholar 

Leijen S et al (2016) Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors. J Clin Oncol 34(36):4371–4380

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sorensen CS et al (2003) Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell 3(3):247–258

Article  CAS  PubMed  Google Scholar 

Vichai V, Kirtikara K (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1(3):1112–1116

Article  CAS  PubMed  Google Scholar 

Xia H et al (2019) Raddeanin A down-regulates androgen receptor and its splice variants in prostate cancer. J Cell Mol Med 23(5):3656–3664

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang D et al (2019) Polyphyllin I induces cell cycle arrest in prostate cancer cells via the upregulation of IL6 and P21 expression. Medicine, 98(44)

Krause WC, Shafi AA, Nakka M, Weigel NL (2014) Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells. Int J Biochem Cell Biol 54:49–59. https://doi.org/10.1016/j.biocel.2014.06.013Epub 2014 Jul 4. PMID: 25008967; PMCID: PMC4160387

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ma T, Bai S, Qi Y et al (2021) Increased transcription and high translation efficiency lead to accumulation of androgen receptor splice variant after androgen deprivation therapy. Cancer Lett 504:37–48. https://doi.org/10.1016/j.canlet.2020.12.037

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang C, Liu Y, Lu Y Evaluating < em > In Vitro DNA Damage Using Comet Assay. Journal of Visualized Experiments, 2017(128)

Guo E et al (2022) WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway. J Exp Med, 219(1)

Gleave ME, Hsieh JT, Wu HC, von Eschenbach AC, Chung LW (1992) Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res 52(6):1598–1605

CAS  PubMed  Google Scholar 

Chou TC, Talaly P (1977) A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J Biol Chem 252(18):6438–6442

Article  CAS  PubMed  Google Scholar 

Lheureux S et al (2021) Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 397(10271):281–292

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cuneo KC et al (2016) Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress. Int J Radiat Oncol Biol Phys 95(2):782–790

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fu S et al (2018) Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy. Expert Opin Investig Drugs 27(9):741–751

Article  CAS  PubMed  Google Scholar 

Bruyer A et al (2023) Combined inhibition of Wee1 and Chk1 as a therapeutic strategy in multiple myeloma. Front Oncol 13:1271847

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garcia TB, Fosmire SP, Porter CC (2018) Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine. Leuk Res 64:30–33

Article  CAS  PubMed  Google Scholar 

Ha DH et al (2020) Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer. Sci Rep 10(1):9930

Article  CAS  PubMed  PubMed Central  Google Scholar 

Parsels LA et al (2011) Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition. Clin Cancer Res 17(11):3706–3715

Article  CAS  PubMed  PubMed Central